Phase III POLO trial: olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer

Phase III POLO trial: olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer

The following article, written by Barry Peterson, Director of Oncology Pharmacy at Oncology Analytics, is the second of a four-part series on key trends and findings from the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago May 31-June 4,...

Subscribe To Our Newsletter

Join our monthly mailing list to receive the latest news and updates from OncoHealth.

You have Successfully Subscribed!